Pan-Her inhibitor is being evaluated as a treatment for early and advanced Her2-positive breast cancer.

Newly established Puma Biotechnology acquired global development and commercialization rights to Pfizer’s Phase III-stage anticancer drug neratinib. The orally administered drug is a multitargeted, irreversible tyrosine kinase inhibitor that targets the ErbB1 (EGFR), ErbB2 (HER2), and ErbB4 (HER4) kinases. It is an irreversible tyrosane kinase inhibitor, which is in development for the treatment of early- and late-stage HER2-positive breast cancer.

Pfizer acquired neratinib when it took over Wyeth back in 2009, but says while oncology remains a priority, it is actively prioritizing its portfolio to decide which compounds to develop internally and which to outlicense. Under terms of the deal with Puma, Pfizer will receive milestones related to development of neratinib, plus sales royalties.

Puma is focused on licensing in anticancer drugs for development. The firm has been set up by Alan H. Auerbach, who also founded and was CEO at Cougar Biotechnology, which Johnson & Johnson took over in 2009. 

Previous articleGilead Negotiates Worldwide License to BI’s Early Clinical Stage HIV Program
Next articleAntisense Therapy Improves Lifespan and Motor Function in Mice with Severe Spinal Muscular Atrophy